DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Wednesday. The firm issued a hold rating on the stock.

Separately, HC Wainwright restated a buy rating and set a $10.00 price target on shares of DBV Technologies in a report on Wednesday, February 21st.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $0.76 on Wednesday. DBV Technologies has a one year low of $0.65 and a one year high of $2.37. The company has a market cap of $145.96 million, a price-to-earnings ratio of -1.97 and a beta of 0.76. The firm has a 50 day simple moving average of $0.85 and a 200 day simple moving average of $0.97.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.10. The company had revenue of $8.88 million during the quarter, compared to analysts’ expectations of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the prior year, the company earned ($0.23) EPS. As a group, analysts expect that DBV Technologies will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in shares of DBV Technologies by 16.5% in the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock valued at $1,093,000 after purchasing an additional 97,412 shares during the last quarter. BNP Paribas Arbitrage SA bought a new stake in DBV Technologies during the second quarter valued at $49,000. ExodusPoint Capital Management LP bought a new stake in DBV Technologies during the second quarter valued at $352,000. Envestnet Asset Management Inc. acquired a new stake in DBV Technologies during the 3rd quarter worth about $67,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of DBV Technologies in the 3rd quarter worth about $26,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.